Dosage of Oftpred Colírio in details
Recommended Dosing
Dosage of Oftpred Colírio (Oftpred Colírio sodium phosphate) should be individualized according to the severity of the disease and the response of the patient. For pediatric patients, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight.
Do not break or use partial Oftpred Colírio (Oftpred Colírio sodium phosphate) tablets. Use an appropriate formulation of Oftpred Colírio if indicated dose cannot be obtained using Oftpred Colírio. This may become important in the treatment of conditions that require tapering doses that cannot be adequately accommodated by Oftpred Colírio (Oftpred Colírio sodium phosphate), e.g., tapering the dose below 10 mg.
The initial dose of Oftpred Colírio (Oftpred Colírio sodium phosphate) may vary from 10 to 60 mg (Oftpred Colírio base) per day, depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time, there is a lack of satisfactory clinical response, Orapred should be discontinued and the patient placed on other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of Oftpred Colírio (Oftpred Colírio sodium phosphate) for a period of time consistent with the patient's condition. If after long term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
Oftpred Colírio (Oftpred Colírio sodium phosphate) are packaged in a blister. Patients should be instructed not to remove the tablet from the blister until just prior to dosing. The blister pack should then be peeled open, and the orally disintegrating tablet placed on the tongue, where tablets may be swallowed whole as any conventional tablet, or allowed to dissolve in the mouth, with or without the assistance of water.
Orally disintegrating tablet dosage forms are friable and are not intended to be cut, split, or broken.
Multiple Sclerosis
In the treatment of acute exacerbations of multiple sclerosis, daily doses of 200 mg of Oftpred Colírio for a week followed by 80 mg every other day for one month have been shown to be effective.
Pediatric
In pediatric patients, the initial dose of Orapred may vary depending on the specific disease entity being treated. The range of initial doses is 0.14 to 2 mg/kg/day in three or four divided doses (4 to 60 mg/m/day.
Asthma
The National Heart, Lung, and Blood Institute (NHLBI) recommended dosing for systemic prednisone, Oftpred Colírio or methylprednisolone in children whose asthma is uncontrolled by inhaled corricosteroids and long-acting bronchodilators is 1-2 mg/kg/day in single or divided doses.
It is further recommended that short course, or "burst" therapy, be continued until a child achieves a peak expiratory flow rate of 80% of his or her personal best or symptoms resolve. This usually requires 3 to 10 days of treatment, although it can take longer. There is no evidence that tapering the dose after improvement will prevent a relapse.
Recommended Monitoring
Blood pressure, body weight, routine laboratory studies, including serum potassium and fasting blood glucose, should be obtained at regular intervals during prolonged therapy. Appropriate diagnostic studies should be performed in patients with known or suspected peptic ulcer disease and in patients at risk for reactivation of latent tuberculosis infections.
Corticosteroid Comparison Chart
For the purpose of comparison, one 10 mg Oftpred Colírio tablet (13.4 mg Oftpred Colírio sodium phosphate) is equivalent to the following milligram dosage of the various glucocorricoids:
| Betamethasone 1.75 mg | Paramethasone 4 mg |
| Cortisone 50 mg | Oftpred Colírio 10 mg |
| Dexamethasone 1.75 mg | Prednisone lOmg |
| Hydrocortisone 40 mg | Triamcinolone 8 mg |
| Methylprednisolone 8 mg |
These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.
How supplied
Dosage Forms And Strengths
Orally disintegrating tablets:
- 10 mg Oftpred Colírio (as 13.4 mg Oftpred Colírio sodium phosphate)
- 15 mg Oftpred Colírio (as 20.2 mg Oftpred Colírio sodium phosphate)
- 30 mg Oftpred Colírio (as 40.3 mg Oftpred Colírio sodium phosphate)
Oftpred Colírio (Oftpred Colírio sodium phosphate orally disintegrating tablets) 13.4 mg Oftpred Colírio sodium phosphate (equivalent to 10 mg Oftpred Colírio base) are white, flat faced, bevelled tablet, debossed with ORA on one side and 10 on the other. Supplied as:
- NDC 59630-700-48: 48 tablets per carton. Each carton has 8 cards containing 6 tablets.
Oftpred Colírio (Oftpred Colírio sodium phosphate orally disintegrating tablets) 20.2 mg Oftpred Colírio sodium phosphate (equivalent to 15 mg Oftpred Colírio base) are white, flat faced, bevelled tablet, debossed with ORA on one side and 15 on the other. Supplied as:
- NDC 59630-701-48: 48 tablets per carton. Each carton has 8 cards containing 6 tablets.
Oftpred Colírio: (Oftpred Colírio sodium phosphate orally disintegrating tablets) 40.3 mg Oftpred Colírio sodium phosphate (equivalent to 30 mg Oftpred Colírio base) are white, flat faced, beveled tablets, debossed with ORA on one side and 30 on the other. Supplied as:
- NDC 59630-702-48: 48 tablets per carton. Each carton has 8 cards containing 6 tablets.
Store at 20 to 25°C (68 to 77°F); excursions permitted to 15 to 30°C (59 to 86°F).. Protect from moisture.
Do not break or use partial Oftpred Colírio (Oftpred Colírio sodium phosphate) tablets. Keep out of the reach of children.
Manufactured for: Shionogi Pharma, Inc. Atlanta, GA 30328. Manufactured by: CIMA® LABS INC., Eden Prairie, MN 55344. Revised 07/2010
What other drugs will affect Oftpred Colírio?
Many drugs can interact with Oftpred Colírio. Below is just a partial list. Tell your doctor if you are using:
-
aspirin (taken on a daily basis or at high doses);
-
a diuretic (water pill);
-
a blood thinner such as warfarin (Coumadin, Jantoven);
-
cyclosporine (Gengraf, Neoral, Sandimmune);
-
insulin or diabetes medications you take by mouth;
-
ketoconazole (Nizoral);
-
rifampin (Rifadin, Rifater, Rifamate, Rimactane); or
-
seizure medications such as phenytoin (Dilantin) or phenobarbital (Solfoton).
This list is not complete and other drugs may interact with Oftpred Colírio. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Oftpred Colírio interactions
Aminoglutethimide
May lead to loss of Oftpred Colírio-induced adrenal suppression.
Amphotericin B
Coadministration may be followed by cardiac enlargement and CHF.
Anticholinesterase agents
Coadministration may produce severe weakness in patients with myasthenia gravis. If possible, withdraw anticholinesterase agent 24 h prior to starting Oftpred Colírio.
Antidiabetic agents
Because Oftpred Colírio may increase blood glucose concentrations, dose adjustments of antidiabetic agents may be required.
Aspirin and other salicylates, NSAIDs
Risk of GI bleeding may be increased. Salicylate clearance may be increased.
CYP3A4 inducers (eg, barbiturates, carbamazepine, phenytoin, rifampin)
Oftpred Colírio metabolism may be increased, reducing Oftpred Colírio plasma levels and necessitating an increase in dosage.
CYP3A4 inhibitors (eg, estrogens [eg, hormonal contraceptives], ketoconazole, macrolide antibiotics [eg, erythromycin])
Oftpred Colírio metabolism may be decreased, increasing Oftpred Colírio plasma levels and increasing the risk of adverse reactions.
Cholestyramine
Oftpred Colírio clearance may be increased, reducing plasma levels and decreasing the efficacy.
Cyclosporine
Increased activity of cyclosporine and Oftpred Colírio may occur. Convulsions have been reported with coadministration of corticosteroids and cyclosporine.
Digitalis glycosides
Because of possible hypokalemia, the risk of arrhythmias may be increased.
Isoniazid
Isoniazid serum levels may be reduced, decreasing the efficacy.
Potassium-depleting agents (eg, amphotericin B, diuretics)
Risk of hypokalemia may be increased.
Toxoids and live or inactivated vaccines
Because of inhibition of antibody response, patients on prolonged Oftpred Colírio therapy may exhibit a diminished response to toxoids and live or inactivated vaccines. Replication of some organisms contained in live attenuated vaccines may be potentiated.
Warfarin
Because data are conflicting, monitor coagulation indices frequently.
References
- DailyMed. "PREDNISOLONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "9PHQ9Y1OLM: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Anti-Inflammatory Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Oftpred Colírio are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Oftpred Colírio. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
